BOD Australia — CBD Medicinal Cannabis Products Profile (2026)

BOD Australia (ASX: BDA) is an Australian medicinal cannabis company with a particular focus on CBD-based products. Founded in Perth, Western Australia, BOD has built its reputation on pharmaceutical-grade CBD preparations — a category increasingly important as Australian prescribers and patients seek high-quality CBD products for anxiety, pain and inflammatory conditions that can be used without significant psychoactive effects.

Company background

Founded: Perth, Western Australia
ASX listing: BOD Australia Limited (ASX: BDA)
Product focus: CBD-dominant medicinal cannabis; pharmaceutical-grade formulations
Key product: MediCabilis (CBD oil)
Distribution: TGA prescription pathway; pharmacy dispensing nationally

BOD Australia entered the medicinal cannabis market focusing on the CBD-dominant segment — a deliberate strategy at a time when many producers were competing for the high-THC flower market. The company pursued pharmaceutical-grade CBD products, including partnerships with European producers to source consistently high-quality CBD for the Australian market.

The company’s flagship product, MediCabilis, became one of the most prescribed CBD oils in Australia and established BOD’s brand identity with prescribers who favour CBD-focused treatment approaches.

MediCabilis — BOD’s flagship CBD oil

MediCabilis is BOD’s primary medicinal cannabis product — a pharmaceutical-grade CBD oil available in multiple concentrations.

What MediCabilis is:

• CBD (cannabidiol) oil in a carrier oil (typically medium-chain triglyceride or olive oil base)
• Available in multiple CBD concentrations (50mg/mL and higher formulations)
• Low THC content (within legal limits, typically <1%)
• Produced to GMP (Good Manufacturing Practice) pharmaceutical standards

What MediCabilis is used for: MediCabilis is prescribed for conditions where CBD’s therapeutic profile — anti-anxiety, anti-inflammatory, analgesic, and potential anticonvulsant effects — is the primary therapeutic target. Common prescribing indications include:

• Anxiety disorders — where CBD’s 5-HT1A receptor activity provides anxiolysis without psychoactive effects
• Chronic pain and inflammation — CBD’s anti-inflammatory mechanisms via COX-2 inhibition and cytokine modulation
• Insomnia — particularly anxiety-related insomnia where CBD addresses the anxious component
• Epilepsy support — as an adjunct to prescribed anticonvulsants (not replacing Epidyolex for Dravet/LGS)
• PTSD — daytime hyperarousal management without impairment
• Autoimmune and inflammatory conditions — where THC’s psychoactive properties are not desired

MediCabilis vs. high-THC products: MediCabilis is a CBD-dominant product — it does not produce significant psychoactive effects for the vast majority of patients. It is appropriate for:

• Patients who cannot tolerate THC’s psychoactive properties
• Daytime use where full cognitive function must be preserved
• First-time cannabis patients who want to begin with non-intoxicating cannabis
• Patients in safety-sensitive occupations (note: trace THC may still appear on drug tests — see below)

Drug driving note: Despite MediCabilis being CBD-dominant, any product containing trace THC (<1%) can potentially produce a positive roadside oral fluid drug test for THC. Zero-tolerance drug driving laws apply. Discuss timing of use with your prescriber if driving is relevant.

BOD’s European sourcing and supply chain

BOD Australia has established sourcing partnerships with European cannabis producers to supplement domestic supply. European — particularly Dutch and UK — medicinal cannabis production has well-established GMP certification and decades of pharmaceutical expertise. BOD’s European sourcing ensures:

• Consistent cannabinoid profiles across product batches
• Independently verified Certificates of Analysis (CoA)
• Pharmaceutical-grade extraction and formulation
• Supply chain resilience independent of Australian production cycles

All imported BOD products meet TGA import licence requirements and Australian pharmaceutical standards.

How to access BOD products

BOD products are only available through the TGA prescription pathway:

1. Consult a prescriber: Book a telehealth appointment or see your GP / specialist. BOD products (including MediCabilis) are available through any TGA-authorised prescriber — not exclusively through BOD-affiliated services.
2. TGA SAS-B or S4 approval: CBD-dominant products like MediCabilis may be available under Schedule 4 (standard prescription drug) as well as SAS-B pathways — discuss with your prescriber which applies to your specific situation.
3. Prescription dispensed through registered pharmacy: Your prescribing pharmacist or online pharmacy will source and dispense MediCabilis or other BOD products.
4. Delivery: National delivery available through online pharmacy partners.

You do not need to contact BOD directly to access their products. BOD sells through the wholesale and pharmacy dispensing chain — as a patient, you interact with your prescriber and pharmacy, not BOD Australia directly.

BOD in the context of Australia’s CBD market

CBD occupies a unique position in Australian cannabis medicine. Unlike high-THC products (Schedule 8 controlled drug), low-dose CBD is available as a Schedule 3 pharmacy product in limited circumstances, and higher-dose therapeutic CBD (Schedule 4) has a somewhat less complex approval pathway.

BOD’s focus on CBD positions it well for:

• The growing patient population seeking non-psychoactive cannabis medicine
• Prescribers cautious about high-THC prescribing for certain conditions (anxiety, first-time patients, older patients)
• Patients transitioning from CBD oil supplementation to pharmaceutical-grade medicinal cannabis
• Conditions where CBD’s evidence base is strongest — anxiety, epilepsy, inflammation

BOD’s company context

BOD Australia is an ASX-listed company and publishes quarterly and annual reports providing transparency into its operations and financials. As the medicinal cannabis market has become more competitive with more than 100 licensed entities in Australia by 2026, BOD has maintained its position by focusing on product quality and the CBD-specialised segment rather than competing across all product categories.

Frequently asked questions — BOD Australia

What is MediCabilis used for? MediCabilis is a pharmaceutical-grade CBD oil prescribed for conditions including anxiety, chronic pain, insomnia, inflammatory conditions and as a support for epilepsy management. It does not produce significant psychoactive effects for most patients.

Does MediCabilis contain THC? MediCabilis is CBD-dominant with very low THC (<1%). The trace THC may be sufficient to produce a positive result on sensitive roadside oral fluid drug tests. Do not drive after using MediCabilis until you understand how your prescription affects test results — discuss this with your prescriber.

Can I buy BOD products without a prescription? No. TGA-registered medicinal cannabis products including MediCabilis require a valid prescription. There is a narrow exception for very low-dose CBD products available over-the-counter in some pharmacies (Schedule 3), but therapeutic doses typically require Schedule 4 prescription.

Is BOD an Australian company? BOD Australia Limited is an ASX-listed Australian company headquartered in Perth, WA. It sources some products from European partners but operates under Australian law and TGA regulation.

How does MediCabilis compare to other CBD oils on the market? MediCabilis is a pharmaceutical-grade product with GMP certification, batch-specific Certificates of Analysis and TGA approval — differentiating it from unregulated CBD supplements sold through health food stores. For therapeutic use, pharmaceutical-grade products with verified cannabinoid content are significantly superior to unregulated supplements.

Is BOD’s CBD available on the PBS? No. MediCabilis and other BOD products are not currently listed on the Pharmaceutical Benefits Scheme for most indications. Patients pay out-of-pocket. CBD for Dravet syndrome and Lennox-Gastaut syndrome is PBS-listed via Epidyolex (a different pharmaceutical CBD product) — discuss with your neurologist if this applies to your situation.